<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Despite advances in treatment options for <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> over the past decade, the number of chemotherapy agents available remains limited </plain></SENT>
<SENT sid="1" pm="."><plain>We report here a retrospective review of 11 patients who were treated with panitumumab following documented disease progression on cetuximab </plain></SENT>
<SENT sid="2" pm="."><plain>Two patients demonstrated minor radiographic responses, albeit only for a short period of time </plain></SENT>
<SENT sid="3" pm="."><plain>We conclude that the use of one epidermal growth factor receptor inhibitor following failure on the other may be of benefit to patients who would otherwise have no other treatment options </plain></SENT>
<SENT sid="4" pm="."><plain>However, studies to help identify the subset of patients who might benefit from this strategy are needed </plain></SENT>
</text></document>